Analysis of the pembrolizumab-sensitive samples based on tumour oestrogen receptor (ER) and progesterone receptor (PR) expression revealed 7/7 were associated with ER+ tumours and 5/7 were associated with ER+/PR+ tumours (Supplementary Fig. 5). Here, PGR is linked to neoplasm.